Quarterly Report · 10-Q
IO Biotech, Inc.
Quarterly Report
Company context
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York. For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Current securities
Historical securities (1)
Recent company filings
- 25-NSE - filed by Nasdaq Stock Market LLC regarding IO Biotech, Inc.Jun 8, 2026
- SCHEDULE 13D/A - filed by Lundbeckfond Invest A/S regarding IO Biotech, Inc.Jun 2, 2026
- SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding IO Biotech, Inc.May 15, 2026
- SCHEDULE 13G/A - filed by HBM Healthcare Investments (Cayman) Ltd. regarding IO Biotech, Inc.Apr 6, 2026
- Bankruptcy or Receivership · Triggering Events That Accelerate or Increase a Direct Financial Obligation · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsMar 31, 2026
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗